教員活動データベース

Very Low-Dose Dasatinib Is a Safe and Effective Therapy for Elderly Patients with Newly-Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results from the Davlec Study, a Single-Arm, Multicenter, Phase 2 Trial

発表形態：: 一般講演（学術講演を含む）
主要業績：: 主要業績
単著・共著：: 共著
発表年月：: 2021年12月

DOI：
会議属性：: 国際会議（国内開催を含む）
査読：: 有り
リンク情報：

日本語フィールド

著者：

*Takashi Kumagai, Kazunori Murai, Hiroshi Ureshino, Hideo Tanaka, Kaichi Nishiwaki, Satoshi Wakita, Koiti Inokuchi, Toshihiro Fukushima, Chikashi Yoshida, Masayuki Mita, Nobuhiko Uoshima, Toru Kiguchi, Jun Aoki, Satoshi Kimura, Kaori Karimata, Kensuke Usuki, Joji Shimono, Yoshiaki Chinen, Junya Kuroda, Yasufumi Matsuda, Kensuke Nakao, Takaaki Ono, Katsumichi Fujimaki, Hirohiko Shibayama, Chisaki Mizumoto, Tomoharu Takeoka, Katsuhiro Io, Takeshi Kondo, Masatomo Miura, Yosuke Minami, Takayuki Ikezoe, Jun Imagawa, Ayako Takamori, Atsushi Kawaguchi, Junichi Sakamoto, and Shinya Kimura

題名：

Very Low-Dose Dasatinib Is a Safe and Effective Therapy for Elderly Patients with Newly-Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results from the Davlec Study, a Single-Arm, Multicenter, Phase 2 Trial

発表情報：

63rd ASH Annual Meeting and Exposition(Hybrid meeting), 2021,12,11-14(On-site and On-line), Atlanta, USA

キーワード：

概要：

抄録：

Blood, 138 (Supplement 1)3601, 632.Chronic Myeloid Leukemia: Clinical and Epidemiological

英語フィールド

Author：

Title：

Announcement information:

63rd ASH Annual Meeting and Exposition(Hybrid meeting), 2021,12,11-14(On-site and On-line), Atlanta, USA

An abstract：

Blood, 138 (Supplement 1)3601, 632.Chronic Myeloid Leukemia: Clinical and Epidemiological